BiotechTube

Patisiran

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin-mediated Amyloidosis With Cardiomyopathy

Conditions

Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy

Trial Timeline

— → —

NCT ID
NCT05505838

About Patisiran

Patisiran is a pre-clinical stage product being developed by Alnylam Pharmaceuticals for Transthyretin-mediated Amyloidosis With Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05505838. Target conditions include Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (6)

NCT IDPhaseStatus
NCT05505838Pre-clinicalCompleted
NCT05023889Phase 1Active
NCT04201418Pre-clinicalCompleted
NCT03862807Phase 3Completed
NCT02510261Phase 3Completed
NCT01617967Phase 2Completed

Competing Products

9 competing products in Transthyretin-mediated Amyloidosis With Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
EplontersenAstraZenecaPhase 3
77
PatisiranAlnylam PharmaceuticalsPre-clinical
20
ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
30
Nucresiran + VutrisiranAlnylam PharmaceuticalsPhase 3
74
ALN-TTRSC04 + PlaceboAlnylam PharmaceuticalsPhase 1
30
EplontersenIonis PharmaceuticalsPhase 3
74
Inotersen + EplontersenIonis PharmaceuticalsPhase 3
74

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3
74
PatisiranPhase 3
74
Givosiran + PlaceboPhase 3
74
Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3
74
LumasiranPhase 3
74